Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) posted its quarterly earnings data on Monday. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.29), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara says its pivotal FORTIFY-HN01 trial is on track for substantial enrollment by year-end, with an interim analysis planned in mid‑2027 to support potential accelerated approval of FICERA.
• Peer‑reviewed phase I‑B data (1,500 mg weekly + pembrolizumab) published in JCO showed deep, durable activity (median DOR 21.7 months; median OS 21.3 months) and the company will present 3‑year follow‑up across cohorts at ASCO.
• Bicara plans an alternative‑dosing randomized study (≈150–200 patients) starting in 3Q testing a 12‑week 1,500 mg weekly induction then either continued weekly or 2,250 mg every‑3‑weeks maintenance, with PFS as the primary endpoint to enable a more practical commercial regimen.
• Financially, the company ended Q1 with about $539.8M in cash and raised $161.8M (net) in February, providing runway into H1 2029, while warning operating expenses will rise as it funds the pivotal trial and builds commercial infrastructure.
• Management changes and commercial hires—Bill Schelman promoted to CMO and Alex Kharazi hired as CCO—signal preparations to transition from clinical stage to a commercial organization ahead of a potential launch.

Bicara Therapeutics Stock Down 2.2%

Shares of NASDAQ BCAX opened at $22.43 on Tuesday. The firm’s 50-day moving average price is $20.74 and its two-hundred day moving average price is $18.08. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $24.25. The stock has a market capitalization of $1.47 billion, a P/E ratio of -8.86 and a beta of -0.57.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BCAX shares. The Goldman Sachs Group restated a “neutral” rating and issued a $18.00 price target on shares of Bicara Therapeutics in a research note on Tuesday. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. Guggenheim initiated coverage on shares of Bicara Therapeutics in a research report on Monday. They issued a “buy” rating and a $42.00 target price for the company. Finally, HC Wainwright upped their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $29.60.

Insider Buying and Selling

In related news, CEO Claire Mazumdar sold 15,000 shares of the company’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $23.61, for a total transaction of $354,150.00. Following the completion of the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at $8,550,408.72. This represents a 3.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $23.00, for a total value of $211,600.00. Following the completion of the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $3,343,165. This represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 174,310 shares of company stock valued at $3,459,283 over the last quarter.

Institutional Trading of Bicara Therapeutics

Large investors have recently modified their holdings of the company. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Larson Financial Group LLC increased its stake in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the period. American Century Companies Inc. bought a new stake in shares of Bicara Therapeutics during the second quarter valued at approximately $103,000. Finally, New York State Common Retirement Fund boosted its position in shares of Bicara Therapeutics by 87.5% during the fourth quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock worth $126,000 after buying an additional 3,500 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.